Compounds > amlodipine

amlodipine and pd 98059

amlodipine has been researched along with pd 98059 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gao, PJ; Marche, P; Stepien, O; Wang, XY; Zhang, YZ; Zhang, ZL; Zhu, DL1
Garcha, RS; Hughes, AD; Sever, PS1
Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A1

Other Studies

3 other study(ies) available for amlodipine and pd 98059

ArticleYear
The inhibitory mechanisms of amlodipine in human vascular smooth muscle cell proliferation.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2000, Volume: 23, Issue:4

    Topics: Amlodipine; Cell Division; Cells, Cultured; Enzyme Activation; Enzyme Inhibitors; Fibroblast Growth Factor 2; Flavonoids; Humans; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Time Factors

2000
Mechanism of action of angiotensin II in human isolated subcutaneous resistance arteries.
    British journal of pharmacology, 2001, Volume: 134, Issue:1

    Topics: Amlodipine; Angiotensin II; Arteries; Benzimidazoles; Biphenyl Compounds; Calcium; Calcium Channel Blockers; Dihydropyridines; Dose-Response Relationship, Drug; Flavonoids; Genistein; Humans; In Vitro Techniques; Nickel; Norepinephrine; Potassium; Ryanodine; Skin; Tetrazoles; Vascular Resistance; Vasoconstriction; Vasoconstrictor Agents

2001
Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
    Arteriosclerosis, thrombosis, and vascular biology, 2010, Volume: 30, Issue:8

    Topics: Amlodipine; Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Calcium Channel Blockers; Cardiovascular Agents; Cells, Cultured; Chelating Agents; Chemokine CCL2; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Egtazic Acid; Enzyme Activation; Flavonoids; Humans; Lipopolysaccharides; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C3H; Mice, Knockout; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Nifedipine; Phosphorylation; PPAR gamma; Protein Kinase Inhibitors; RNA Interference; RNA, Messenger; Time Factors; Transfection

2010